CRSP vs VRTX: How CRISPR Therapeutics AG and Vertex Pharmaceuticals Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CRSP and VRTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CRSP and VRTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. The company uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines across hemoglobinopathies, oncology, cardiovascular disease, autoimmune conditions, and regenerative medicine. Its first and only commercialized product, Casgevy, is co-developed and co-commercialized with Vertex Pharmaceuticals under a 40/60 profit-sharing structure in which CRISPR retains 40 percent of profits. Revenue has historically been driven by collaboration milestone payments from Vertex rather than product sales, making the financial profile highly lumpy. Beyond Casgevy, the company generates no meaningful product revenue today and funds operations through its cash reserves.

Full CRSP guide

Vertex Pharmaceuticals is a Boston-based biotechnology company that designs medicines targeting the root molecular cause of serious diseases rather than only their symptoms. Its foundation is cystic fibrosis (CF), a genetic disease in which a defective CFTR protein disrupts salt and water movement in cells, damaging the lungs and other organs. Vertex developed the first drugs that correct the underlying protein defect, progressing from Kalydeco to Orkambi and Symdeko and then to the breakthrough triple-combination Trikafta (marketed as Kaftrio in Europe), which treats the large majority of CF patients. In late 2024 it began rolling out Alyftrek, a next-generation once-daily successor designed to extend that franchise and its patent protection. Because CF is a rare disease with essentially no competing root-cause therapy, Vertex has enjoyed pricing power and durable, high-margin revenue.

Full VRTX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CRSP drivers: First-Mover Advantage in Commercial Gene Editing; Casgevy's Long-Term Revenue Potential.
• VRTX drivers: A durable, high-margin cystic fibrosis near-monopoly; Journavx opens a large non-opioid pain market.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. For VRTX, the central risk is revenue concentration: cystic fibrosis still accounts for the overwhelming majority of Vertex's sales, so any disruption, whether a safety signal, a competing modulator, or pricing pressure, would hit the core disproportionately, and the newer products remain small by comparison.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CRSP if you believe its drivers more; VRTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CRSP and VRTX guides.

CRSP. Because CRISPR Therapeutics has no meaningful product profits yet, traditional earnings-based valuation multiples like P/E are negative and not analytically useful. The company is better evaluated on its cash runway, the pace of Casgevy's commercial adoption, and the risk-adjusted value of its pipeline. Enterprise value of roughly $2.8 billion (market cap less net cash) reflects the market pricing in significant execution uncertainty around both the Casgevy ramp and the broader pipeline, while a wide spread exists between bearish analyst targets near $33 and optimistic targets above $80.

VRTX. Vertex trades at a premium to the large-cap pharma average, with a trailing P/E near the high 20s and a forward P/E around 25, reflecting both its high margins and near-monopoly economics in cystic fibrosis and the market's expectation that the pain, cell-therapy, and pipeline programs will add a second and third growth engine. Because the CF franchise is so profitable and the balance sheet holds substantial net cash, much of the valuation debate is about how much credit to give unproven pipeline assets. Vertex does not pay a dividend, so returns depend entirely on earnings growth and multiple, which makes clinical and launch execution the key swing factors.

Headline figures (approximate, June 27, 2026 (data reflects most recently available reports through mid-2026)): CRSP shows revenue (full year 2025, product only) ~$3.5 million, revenue (full year 2024) ~$37.3 million (primarily collaboration revenue), net loss (ttm through q3 2025) ~$488 million, operating loss (full year 2025) ~$665 million; VRTX shows revenue (fy 2025) ~$12.0 billion, revenue growth (fy 2025) ~9%, revenue guidance (fy 2026) ~$12.95 billion to $13.1 billion, trailing p/e (approx.) ~29x.

CRSP and VRTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CRSP and VRTX exposure against your real portfolio. It is not an investment adviser.